A Study of Radiation With Sorafenib in Advanced Cancer
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the combination of radiation treatment and an
anti-angiogenic drug called sorafenib (or BAY 43-9006 or Nexavar) to determine the effects of
this combination on cancers but also on side effects of radiation treatment. This study will
also determine the highest safe dose of sorafenib that can be given with radiation treatment.